glp-1 receptor agonists and cancer risk in adults with obesity Study Finds May Reduce GLP-1 receptor agonists and cancer
Description
Ditzenberger GL, Lake JE, Kitch DW, Kantor A, Muthupillai R, Moser C, et al
Lancet 2023;402:61326.PubMed 94
Diabetes 68 , 3444 (2019)
By contrast, MACE risk was significantly lower among those who continued GLP-1RA use for 2 and 2.5 years, and lowest among those who maintained treatment for three years
The authors emphasized the limitations of their findings, again with no proof that the drugs caused the problems
DOI: 10.1016/j.apsb.2021.04.001, Rajput, R., Ghosh, S., Banerjee, S., et al
